Funding is growing unevenly
The latest figures show more capital, without a broad return to easy fundraising.
U.S. digital health startups raised $11.1 billion across 358 deals through Q3 2026, according to Rock Health’s October market update. The average deal reached $31 million, compared with $29.5 million in 2025 and $20.6 million in 2024. Capital continues to concentrate in larger rounds.
That is the starting point for healthtech investment in 2027: an active market with sharply different fundraising conditions across companies. AI attracts attention, but the label alone says increasingly little about what a business sells or why customers will keep buying it.
The market at a glance
Funding and exits tell different parts of the story.
| Indicator | Through Q3 2026 |
|---|---|
| U.S. digital health venture funding | $11.1 billion |
| Venture deals | 358 |
| Average deal size | $31 million |
| Digital health acquisitions | 164 |
Source: Rock Health Q3 2026 market update
Rock Health recorded 45 acquisitions in Q3, bringing the year-to-date count close to the 172 recorded over the same period in 2025. Public exits remained quieter: its October 9 report noted no new listings since HeartFlow in August 2025.
The distinction matters. A well-funded company may have resources to expand, while its investors still face uncertainty about when and how they can exit.
Healthcare AI is outgrowing the label
Documentation, clinical information and revenue cycle are increasingly connected bets.
AI-enabled companies captured 54% of U.S. digital health funding in 2025, up from 37% in 2024. Clinical and nonclinical workflow companies together attracted 39% of funding that year. Those categories overlap and should not be added together. Source: Rock Health’s 2025 funding analysis.
By Q1 2026, Rock Health had retired its separate AI deal analysis, explaining that the distinction was blurring as AI became embedded in how companies build and deliver their products.
The individual deals are more revealing:
- Ambient documentation: Ambience Healthcare announced a $243 million Series C in July 2025 for its platform spanning documentation, coding and clinical documentation integrity. The financing backed a broader product scope than note generation alone.
- Revenue cycle: Abridge’s June 2025 announcement of a $300 million Series E outlined plans to bring revenue cycle intelligence earlier into clinical documentation. Its stated direction connects the patient conversation with downstream reimbursement work.
- Clinical information and AI infrastructure: Rock Health’s Q1 2026 overview included a $250 million round for medical search company OpenEvidence and $125 million for Qualified Health’s AI adoption and governance platform.
These examples illustrate where investors have committed capital; they do not establish which category will deliver the strongest returns. They also show why simple sector rankings can mislead. A documentation company expanding into coding may compete for several budgets and against several types of vendor.
Valuations have split, rather than simply reset
Pandemic-era pricing still affects some companies while others command new premiums.
The valuation reset has not been uniform. Rock Health’s 2025 analysis described companies still carrying valuation overhangs from earlier rounds alongside AI businesses raising successive large rounds at rapidly increasing valuations. It also found that 35% of venture rounds were unlabeled, meaning they did not represent a conventional step up to the next funding stage.
A recent headline valuation is therefore a weak comparable on its own. Stage, growth and financing terms all affect the comparison. A larger round can fund expansion, extend runway or do both; the amount raised does not reveal the company’s economics.
For founders, an ambitious valuation also raises the bar for the next financing. For investors, the question is how much commercial progress the entry price already assumes.
A large round is not a customer verdict
Financing demonstrates investor conviction. Renewals test whether buyers agree.
When assessing a funded company, look beyond announced partnerships to paid deployments, expansion and retention. A successful pilot and a repeatable enterprise sale are different milestones.
Strategic capital adds another layer
A healthcare investor can bring commercial relevance without guaranteeing adoption.
Traditional venture firms are sharing rounds with investors tied to healthcare organizations. Ambience’s Series C, for example, included Optum Ventures alongside financial investors such as Oak HC/FT and Andreessen Horowitz.
That participation may offer useful industry relationships. It should still be assessed separately from a purchasing commitment. An equity investment, a pilot agreement and a multiyear customer contract provide different evidence about a company’s prospects.
For health system and payer venture teams, this creates a dual decision: whether the company is attractive as an investment and whether its product fits an operational need. One does not automatically resolve the other.
Take the investment thesis to HIMSS27
Meet founders alongside the organizations they need to sell to.
The funding data identifies where conviction is building. Conversations with buyers can help test the assumptions behind it: who controls the budget, what implementation requires and whether a product solves a problem important enough to displace existing spending.
Emerge at HIMSS27 brings an investor and startup focus to that setting. Explore the program and register for HIMSS27 to connect with founders and healthcare decision-makers.